Connect with us

BUSINESS

Generex Biotechnology Corporation (OTCMKTS:GNBT) Launches A Vaccine Development Effort to Address the Newly Identified Swine Influenza Virus

Published

on

For the last couple of months, the world has experienced panic and disarray from the outbreak and the rapid spread of coronavirus. However, it is now emerging that there could be an impending threat of a newly identified virus. According to Generex Biotechnology Corporation (OTCMKTS:GNBT), the virus, which killed almost 500,000 people globally in 2009, is similar to swine flu, though with a few changes.

Of particular concern is that the virus is carried by pigs and could become a viral pandemic if not closely monitored. Its high levels of antibodies to the G4 EA H1 influenza virus is a clear indicator that it can infect humans.

The Launch Of Vaccine Development Efforts To Address The Pandemic Threat

According to Prof Kin-Chow Chang, the new virus may not be an immediate problem. However, it should not be ignored because flu viruses are constantly changing. Speaking to BBC Chang noted, “Right now we are distracted with coronavirus and rightly so. But we must not lose sight of potentially dangerous new viruses.”

Meanwhile, NuGenerex Immuno-Oncology is putting together efforts to develop a vaccine, which could help mitigate the spread of the virus. The company’s CEO Joseph Moscato says that through its Ii-Key immune activation technology, they have what it takes to create targeted and highly specific vaccines.

Ii-Key peptide vaccines have previously demonstrated quick and effective responses to viral and cancer antigens without signs of cytokine storm effects in the two trials conducted to date. Thus, it is a perfect fit for inclusion in a pandemic preparedness portfolio. Besides, NGIO has the infrastructure and extensive experience responsiveness to pandemic threats.

We Need To Be Vigilant Even During the COVID-19 Pandemic

COVID-19 pandemic seems to have taken away all the attention to any other health matters. This is according to the World Health Organization, which emphasizes the need for vigilance. Farmed animals, which sometimes act as a source of the pandemic virus, are in constant contact with humans. On the other hand, new pathogens are emerging every day.

WHO further outlines that flu could occur anytime, and as a result, there is frequent review of information on both new and old viruses. The review happens during the influenza vaccine composition meetings held twice a year.

BUSINESS

Skylight Health Group Inc (OTCMKTS:SHGFF) Inks A Deal With A Leading Clinical Research Group – ClinEdge

Published

on

Skylight Health Group Inc (OTCMKTS:SHGFF) signed a deal with ClinEdge in April 2021. The deal allows the company to offer sponsored trials to Massachusetts-based primary care practices.

Besides promoting clinical research, the pact shows the value of the diversity of Skylight in healthcare services in the US.

Full suite of services

With more than 10 years of experience in partnering clinical research (CR) sites with research sponsors, ClinEdge offers a full suite of support services for the clinical research institutions, sponsors, and CROs.

Its main target is developing and improving service lines at affordable rates besides ensuring accuracy and timeliness of administering CR. The company’s established relationships with Clinical Research Organizations (CROs) and industry sponsors promote the successful generation of leads for clinical trials.

The company closely works with CR sites to receive CR trials from reputed and experienced industry sponsors. CR Manager of Skylight, Alisha Garibaldi, said entering pacts with partners like ClinEdge shares its vision on promoting quality CR that benefits the patients and improves its growth. It also ensures the growth of the healthcare systems in the US on a large scale.

He further said the company is excited to enter a deal with ClinEdge, which provides unparalleled experience in the CR.

The experience of ClinEdge allows the teams at Skylight to engage in CR trials that investigate a wide gamut of indications beginning with Massachusetts-based clinical sites. It allows Massachusetts-based patients to participate in clinical trials and enjoy new therapies, vaccines, and treatments.

Contributes to the medical sciences community

Skylight, which knows the value of clinical research, intends to offer the best care to its patients besides contributing to the medical sciences community at large. After achieving success at Massachusetts CR, the company intends to replicate the same across the US by expanding partnerships.

The clinical trial opportunities that ClinEdge will bring comprise post-traumatic stress disorder, COVID-19, arthritis, diabetes, and hypertension. Skylight will offer trial opportunities to its existing patients and individuals interested in taking part in the CR.

Skylight will earn up to $15,000 for each patient trial. It will offer a stipend to the patients who took part in the clinical trial for their efforts and time.

Skylight will report Q4 2020 and full-year earnings on April 20, 2021.

Continue Reading

BUSINESS

Can B Corp (OTCMKTS:CANB) Takes Over Talents And Assets Of Hemp Derivative Development And Manufacturing Group

Published

on

Can B Corp (OTCMKTS:CANB) took over a hemp derivative development/ manufacturing group’s talent and assets. Botanical Biotech LLC, its newly created subsidiary, will be its R&D and extraction facility based in Florida.

Can B will use Botanical Biotech, which President – Bradley Lebsock will be headed for developing and implementing its innovative pharmacokinetics technology. Botanical Biotech will also partner with emerging and global brands in developing innovative products/ solutions for wellness benefits.

Botanical Biotech engages in optimizing plant-based formulations to provide bioactive compounds and offers a consistent experience for the consumers in the long term. It will improve the solubility and absorption of bioactive compounds using various strategies.

Botanical Biotech’s expertise allows manipulating the molecules and offering economic formulations together with articulating the distinct value propositions of a formula using its communications and marketing teams.

Expertise in extracting hemp isolate

The Botanical Biotech team is experienced in extracting hemp isolate into CBN, CBG, and other cannabinoids. CBG and CBD are non-intoxicating cannabinoids and provide anti-inflammatory effects to your body. They will not create any high and offers only health benefits.

The CEO of Can B, Marco Alfonsi, said the company is thrilled to bring Bradley’s team under one umbrella and use their scientific approach to develop innovative products besides the existing products. Botanical Biotech’s science-based technology and product development expertise help Can B’s proprietary brands as well as Pure Health Products manufacturing facility based in WA.

Mobilizes $2.8 million

Can B generated $2.8 million cash through a debt financing deal from an institutional investor. The company will use these funds to pay all the convertible notes outstanding as of today. It will also use a certain portion of the funds and Reg A offering for working capital needs to promote growth in 2021.

Can B has started its operations in 2021 with an enhanced zeal. The company developed a vertically integrated platform to control its products from seed-to-sale offering high-quality products to the consumers in the previous year.

Its Pure Health Products expects to achieve GMP certification in Q1 2021. Pure Health Products also secures new white label clients.

Continue Reading

BUSINESS

Tinley Beverage Company Inc (OTCMKTS:TNYBF) Ships First Batch Of Third Party Products From Its Long Beach, California Based Facility

Published

on

Tinley Beverage Company Inc (OTCMKTS:TNYBF) shipped its first batch of third-party products manufactured at its Long Beach, California-based facility. Also, a leading cannabis and cannabidiol beverage brand – Good Stuff Beverage Co will move its natural tonics production to Tinley’s facility.

Good Stuff’s classic flavors comprise a new and terpene-infused formula. It will demonstrate the launch of high dose and strain-specific tonic.

Its product line comprises the Original Honey Lemonade, Sativa Energy, and Indica Calm. Consumers can use a resealable bottle cap to take an exact dose and sip easily.

President (West Coast USA) of Tinley, Rick Gillis, said any company usually faces challenges in manufacturing fruit-infused drinks while ensuring shelf stability and quality. Its team of food process and quality experts and specialized production equipment will play a vital role in delivering the required stability and consistency for this fruit-derived brand.

The cannabis community in California has well-accepted the products of Good Stuff. Therefore, they will love to receive enhanced formula-based products from Good Stuff.

Co-founder of Good Stuff, Daniel Grim, said Good Stuff Beverages is an excellent Tinley value proposition. The custom-built equipment and talented team of Tinley will help Good Stuff in its scalability.

Distribution boost through retail in Alberta

Tinley said its product distribution continues to improve through enhanced retail stores in Alberta. It also receives requests from provincial buyers for cannabis products.

According to a communiqué from local agents, the company received commitments or listings for its ready-to-drink cocktails and Beckett’s non-alcoholic spirits at 30 retailers across Alberta. The company is excited to receive reorders within one week of the initial listings.

Raises $850,000

Tinley raised a capital of $850,000 through a non-brokered private placement of 2.125 million units at $0.40.

Manufactures zero-calorie sparkling drinks

Tinley is pleased to announce that its Long Beach facility will manufacture Calexo’s four preservative-free juice beverages and zero-calorie sparkling drinks.

Innovative cannabis blended sparkling waters, which are branded as Watercolors, will be blended with 5mg THC and natural botanicals in a 12oz bottle. It is developed for those looking to replace alcohol.

Continue Reading

Trending Stories